Liquid-liquid phase separation has been shown to underlie the formation and disassembly of membraneless organelles in cells, but the cellular mechanisms that control this phenomenon are poorly understood. A prominent example of regulated and reversible segregation of liquid phases may occur during mitosis, when membraneless organelles disappear upon nuclear-envelope breakdown and reappear as mitosis is completed. Here we show that the dual-specificity kinase DYRK3 acts as a central dissolvase of several types of membraneless organelle during mitosis. DYRK3 kinase activity is essential to prevent the unmixing of the mitotic cytoplasm into aberrant liquid-like hybrid organelles and the overnucleation of spindle bodies. Our work supports a mechanism in which the dilution of phase-separating proteins during nuclear-envelope breakdown and the DYRK3-dependent degree of their solubility combine to allow cells to dissolve and condense several membraneless organelles during mitosis.
A fundamental property of inhomogeneous crowded fluids is their ability to display coacervation, electrostatically driven liquid-liquid phase separation of molecules, which can lead to the emergence of micro-compartments 1, 2 . This phase-separation paradigm has in recent years been successfully applied to explain the formation of numerous membraneless organelles in cells, a process that is driven by intrinsically disordered regions in proteins and weak multivalent interactions [3] [4] [5] , and often aided by polymeric scaffolds such as RNA to which these proteins bind 6, 7 (in some cases, the scaffolds themselves can also induce phase separation 8 ). However, as with all cellular processes, various gene functions and enzyme activities must have evolved to modulate the underlying physicochemical phenomenon, to drive it out of equilibrium or to push it across critical boundaries to make it advantageous for living systems.
We previously discovered that upon cellular stress, the dualspecificity kinase DYRK3 partitions into stress granules via its intrinsically disordered N-terminal domain and that its kinase activity is required for the dissolution of stress granules, probably by phosphorylating multiple RNA-binding proteins 9 . Also, it was shown that MBK-2, the Caenorhabditis elegans homologue of DYRK3, controls the dissolution of P-granules during the first cell division of the embryo 10 through phosphorylation. In addition, POM1, a Saccharomyces pombe relative of DYRK3, displays reversible clustering 11 and controls the presence of protein assemblies involved in cytokinesis 12 , which may also involve phase separation. Thus, DYRK-family kinases could represent a novel class of evolutionarily conserved cellular regulators that control phase-transition phenomena in cells, serving various cell-physiological purposes.
A notable example of such control may occur during mitosis. It has long been known that numerous membraneless organelles in both the cytoplasm and the nucleus disappear during mitosis, or, in the case of stress granules, cannot be induced to form in mitotic cells [13] [14] [15] . However, the physical principles and the molecular mechanisms behind these phenomena have remained unclear. We here investigate whether DYRK3 acts as the dissolvase in these processes, and how this is coordinated with the cell cycle.
DYRK3 interactome and localization
To identify proteins that interact with DYRK3 in unperturbed cells, we performed quantitative affinity purification using stable-isotope labelling with amino acids in cell culture (SILAC)-based quantitative proteomics 16 . From two independent label-swap experiments (forward and reverse) (Extended Data Fig. 1a ), we identified a total of 251 proteins that interact specifically with transiently overexpressed EGFPtagged DYRK3 (Fig. 1a, Supplementary Table 1 ). The majority (86%) of these proteins are known to bind RNA, and amongst them are multiple components of stress granules, splicing speckles and the centrosome or pericentriolar matrix (Fig. 1a) . Moreover, when we treated cells with GSK-626616, a small-compound inhibitor of DYRK3 9 , many of these interactions became more prominent (Fig. 1b, Extended Data Fig. 1b , c, Supplementary Table 2) , independently of any increase in the abundance of the corresponding interactors or of DYRK3 itself (Extended Data Fig. 1d, e) .
Overexpression of DYRK3 leads to its spontaneous phase separation at a specific concentration threshold 9 . To investigate its subcellular localization at near-endogenous levels, we created an inducible cell line. At very low induction levels (approximately 30% of endogenous levels) (Extended Data Fig. 2a ), EGFP-DYRK3 shows a diffuse distribution within the nucleus and the cytoplasm, but also an enrichment in centrosomes (pericentrin) and the pericentriolar matrix (PCM1) (Fig. 1c) , and in splicing speckles (SC35) (Fig. 1d) . Inhibition of DYRK3 leads to a further accumulation in splicing speckles, and to a visible increase in the size of splicing speckles (Fig. 1d) . Consistent with our previous findings 9 , EGFP-DYRK3 that is inhibited by GSK-626616 also accumulates in arsenite-induced stress granules (PABP1) at these low expression levels (Extended Data Fig. 2b) . In mitotic cells, we observed that EGFP-DYRK3 localizes to spindle poles, and that it accumulates in small granules that grow in size when its kinase activity is inhibited (Fig. 1e, Extended Data Fig. 2c ).
Mitotic effects of DYRK3 inhibition
Because DYRK3 associates with membraneless organelles in both the nucleus and the cytoplasm, accumulates in granules in mitotic cells when inhibited, and interacts with proteins that are heavily Article reSeArcH phosphorylated during mitosis (some of which contain sites that are sensitive to DYRK3 inhibition 9 (Extended Data Fig. 2d )), we decided to investigate its role during mitosis, when the contents of both cellular compartments mix. Notably, we found that inhibition of DYRK3 in mitotic cells leads to aberrant condensations of the splicing-speckle marker SC35 (Fig. 2a, Extended Data Fig. 3a) , the stress-granule marker PABP (Fig. 2b, Extended Data Fig. 3b ) and the pericentriolarmaterial protein PCM1 (Fig. 2c, Extended Data Fig. 3c ). Aberrant condensations were observed in two different human cell lines and for multiple markers (Extended Data Fig. 3d-f) . Testing a panel of kinase inhibitors that are known to regulate centrosome biogenesis or splicingspeckle composition in interphase cells did not show these effects (Extended Data Fig. 3g ). Moreover, GSK-626616 does not cause the accumulation of SRPK1 17 or CDK1, a key regulator of entry into mitosis, in these aberrant condensations, nor does it affect their activation or activity inside cells (Extended Data Fig. 4a-f ) or in vitro 9 , whereas RNA interference-mediated knockdown of DYRK3 recapitulated the effects of GSK-626616 (Extended Data Fig. 4g) .
Notably, splicing-speckle, stress-granule and pericentriolar-matrix markers co-condensed into the same hybrid structures, which also stained positive for polyadenylated RNA and accumulated inhibited DYRK3 (Fig. 2d , e, Extended Data Fig. 5a, b) . Not all markers of membraneless organelles condensed into these structures, as P-bodies, nucleoli, and Cajal bodies appeared to dissolve normally during mitosis even when DYRK3 was inhibited (Extended Data Fig. 5c-e) . The aberrant condensates are not classical aggresome-like structures, as they do not stain positive for ubiquitin (Extended Data Fig. 5f ). Time-lapse analysis of mitotic granule formation using mCherry-tagged SRRM2, a splicing-speckle protein, revealed that they appear fast (within 15-20 min) upon DYRK3 inhibition (Fig. 2f, Supplementary Video 1) and display liquid-like merging (Extended Data Fig. 6a ), whereas photobleaching the granules showed that SRRM2 exchanges rapidly (with a recovery half-time of approximately 10 s) and completely between the condensed and dissolved phases (Fig. 2g) . The total amount of SRRM2 in cells did not change during granule formation (Extended Data Fig. 6b) , and the accumulation of SRRM2 in the condensed phase was a consequence of its depletion from the dissolved phase (Extended Data Fig. 6c) . Thus, DYRK3 kinase activity is essential during mitosis to prevent the formation of aberrant liquid-liquid phase-separated hybrid condensates consisting of nuclear and cytoplasmic proteins and RNA, by keeping the condensation threshold of its substrates high.
DYRK3 dissolvase activity
To prevent aberrant condensation, DYRK3 may act as a dissolvase of multiple liquid-unmixed compartments. When we overexpressed wild-type EGFP-DYRK3 in interphase cells, we observed dissolution of splicing speckles in the nucleus (Fig. 3a, b, Extended Data Fig. 7a ). This dissolving effect was dependent on its kinase activity, as it was reversed by treating cells with the DYRK3 inhibitor, and was not observed when overexpressing a kinase-dead point mutant of EGFP-DYRK3 (Fig. 3a, b , Extended Data Fig. 7a, b ). Moreover, a nuclear-localization sequence mutant of DYRK3 prevented the dissolution of splicing speckles, whereas exclusive nuclear localization of DYRK3 completely dissolved splicing speckles, indicating that this sequence is required for the direct interaction with its substrates (Extended Data Fig. 7c, d) .
Similarly, we found that overexpression of EGFP-DYRK3 dissolves pericentriolar satellites and prevents the induction of stress granules with arsenite in the cytoplasm in a kinase-activity-dependent manner ( Fig. 3c-f , Extended Data 7e-h). Furthermore, phase-separated structures formed by overexpressing an intrinsically disordered domain of PCM1 (1-1468) 14 and SRRM1, a highly intrinsically disordered interactor of DYRK3 and known splicing-speckle component (Extended Data Fig. 7i ), are completely dissolved by DYRK3 in a kinase-dependent manner (Extended Data Fig. 7j-l) . We did not observe a dissolving effect of overexpressed DYRK3 on nucleoli (Extended Data Fig. 7m) , consistent with the observation that these organelles still dissolve in DYRK3-inhibited mitotic cells. This shows that kinase-active DYRK3 has dissolvase activities for multiple but not all membraneless organelles, both in the cytoplasm and in the nucleus.
DYRK3-to-substrate ratio drives phase transition
Upon entry into mitosis, membraneless organelles disappear, and then reappear during telophase or after completion of mitosis [13] [14] [15] 18 . If disappearance occurs through a dissolution process driven by DYRK3, then its dissolvase activity must rapidly increase at the beginning of mitosis and then reduce at the end of mitosis. When we analysed the protein levels of endogenous DYRK3 along the cell cycle, we observed that its expression increases as cells progress from late S to the end of G2 (Fig. 4a ). Yet, cells in late G2 display splicing speckles in the nucleus and can condense stress granules in the cytoplasm upon stress 13, 15, 18 . Furthermore, we did not observe a sudden increase in DYRK3 levels as cells enter mitosis (black box in Fig. 4a) .
One explanation could be that the concentration of DYRK3 relative to its substrate suddenly increases upon breakdown of the nuclear envelope. This occurs because key substrates of DYRK3 are exclusively located in either the nucleus (SRRM1) or the cytoplasm (PCM1), resulting in their dilution when the compartment barrier is removed (Fig. 4b, Extended Data Fig. 8a-d) . And because DYRK3 itself is located in both compartments and does not get similarly diluted, the DYRK3-to-substrate ratio increases by a factor of two to three (Fig. 4b) as cells transition from G2 into M. To investigate whether such an increase in ratio is necessary and sufficient to ensure complete dissolution of membraneless organelles during mitosis, we transiently transfected inducible wild-type EGFP-DYRK3 along with mCherry-SRRM1 in non-mitotic cells. From a large number of single cells covering a wide Article reSeArcH range of expression levels and DYRK3-to-SRRM1 ratios, we determined an intracellular phase diagram of SRRM1 in a condensed or dissolved phase as a function of DYRK3 and SRRM1 levels. This revealed a remarkably sharp phase boundary at a specific DYRK3-to-SRRM1 ratio across a large range of expression levels, below which SRRM1 would be condensed and above which it would be dissolved (Fig. 4c) . Furthermore, by following interphase cells using time-lapse imaging, we could observe how changes in the concentration of the components determine granule phase behaviour as mapped in the phase diagram.
Cells in which the DYRK3-to-SRRM1 ratio increased over time displayed a sudden transitioning from a condensed SRRM1 phase to a dissolved phase when the phase boundary was crossed (cells 1 and 2 in Fig. 4d ). Consistently, SRRM1 remained dissolved in cells that always displayed a high DYRK3-to-SRRM1 ratio and stayed above the phase boundary over time (cell 3 in Fig. 4d ). We next focused on single cells with low, near-endogenous levels of EGFP-DYRK3 and mCherry-SRRM1 that entered mitosis during the time-lapse recording. When we plotted single-cell time traces of DYRK3-to-SRRM1 ratios into the phase diagram, and marked when SRRM1 becomes dissolved, we observed that this occurs right at the moment of crossing the phase transition boundary (cells 1 and 2 in Fig. 4e ), owing to the sudden, 2.7-fold increase in DYRK3-to-SRRM1 ratio during the G2-to-M transition (marked by arrowheads in Fig. 4e ). Consistently, when we followed a cell with high levels of overexpressed SRRM1 and a consequently very low DYRK3-to-SRRM1 ratio far away from the phase transition boundary, the 2.7-fold increase in the ratio during the G2-to-M transition was not sufficient to cross the boundary, resulting in the persistence of SRRM1 granules in mitotic cells (cell 3 in Fig. 4e ). We observed this effect invariably in single cells that overexpress SRRM1 beyond a critical concentration, at which point levels of endogenous DYRK3 were insufficient to trigger a phase transition upon mitotic entry (Fig. 5a ). These cells show mitotic SRRM1 granules (Fig. 5a ) that recruit endogenous splicing-speckle proteins (Extended Data Fig. 8e ), which also undergo liquid-like merging, and show rapid exchange of SRMM1 between the condensed and dissolved phase, which is under the control of DYRK3 (Extended Data Fig. 8f,  g ). Furthermore, we observed that the dilution effect alone is not sufficient. When we arrested cells in mitosis after nuclear-envelope breakdown with a single thymidine-nocodazole block, and splicing speckles are dissolved, acute treatment with the DYRK3 inhibitor results in the appearance of aberrantly condensed structures (Extended Data Fig. 8h ), indicating that DYRK3 kinase activity is required to maintain the dissolved phase during mitosis.
Aberrant granules delay mitotic progression
We next asked whether the aberrant co-condensation of proteins in mitotic cells has a consequence for mitotic progression. We found that when cells are treated with the DYRK3 inhibitor, they display a prolonged mitotic length, and often a mitotic arrest (Fig. 5a ). Notably, we also found a prolonged mitotic length in cells that were unable to completely dissolve mitotic granules upon nuclear-envelope breakdown owing to very high levels of overexpressed SRRM1, even when DYRK3 
Article reSeArcH activity was not compromised (Fig. 5a ). This suggests that mitotic defects are, in part, caused by an inability to keep proteins dissolved in mitotic cells. Notably, although centrosome duplication appears to occur normally in DYRK3-inhibited cells, γ-tubulin displays multiple condensation foci (Extended Data Fig. 9a ), resulting in the frequent occurrence of multipolar spindles (Fig. 5b) . To explain this, we searched the DYRK3 interactome for possible mitotic regulators that might have an impact on mitosis. This revealed that ZNF207 (BuGZ) and its interaction partner BUB3 are enriched in the DYRK3 interactome upon GSK-626616 treatment (Fig. 5c, Supplementary Table 2 ). ZNF207 is required for spindle matrix assembly through liquid-liquid phase separation 19 , and localizes to splicing speckles in interphase cells 20 (Extended Data Fig. 9b ). When we analysed its localization in mitotic cells, we found that upon DYRK3 inhibition, ZNF207 also becomes sequestered in mitotic granules in which it colocalizes with inhibited DYRK3 (Extended Data Fig. 9c , d) and PABP (Fig. 5c ). Thus, DYRK3 releases mitotic regulators from liquid-unmixed compartments at the onset of mitosis and keeps them dissolved during mitosis. When this is compromised, mitotic regulators are sequestered in mitotic granules, which interferes with their normal roles during mitosis leading to mitotic defects. At the end of mitosis, reassembly of the nuclear envelope and the reaccumulation of DYRK3 substrates in their respective compartments should cause the DYRK3 dissolvase-to-substrate ratio to drop below the critical point and reverse this process. However, some membraneless organelles, such as splicing speckles, recondense in telophase 18 , before the nuclear envelope has been reassembled. Notably, we noticed that DYRK3 is abruptly degraded at the boundary between M and G1 (red box in Fig. 4a and Fig. 5d ), suggesting that recondensation before nuclear envelope reassembly may rely on rapidly removing DYRK3. Progression through mitosis and entry into G1 is driven by the anaphase promoting complex/cyclosome (APC/C), which promotes the ordered ubiquitination and subsequent degradation of multiple D-box (RXXL)-containing substrates through mitosis 21 . We found that DYRK3, which contains a D-box, interacts with both APC/C co-activators CDC20 and CDH1, resulting in its targeting to ubiquitin-positive aggregates in the cytoplasm and its degradation ( Fig. 5e and Extended Data Fig. 10a-d) , consistent with the identification of DYRK3 as a novel APC/C substrate 22 . Moreover, when we overexpressed EGFP-DYRK3 in mitotic cells to levels that cannot be degraded by APC/C, splicing speckles remained dissolved in telophase, indicating that APC/Cmediated degradation of DYRK3 at the end of mitosis is involved in their recondensation process (Extended Data Fig. 10e ).
Discussion
Here, we have uncovered a mechanism by which multiple membraneless organelles dissolve during mitosis and recondense as mitosis completes. The dual-specificity kinase DYRK3 has a key role in this process by acting as the dissolvase of these organelles. This extends our previous finding that DYRK3 dissolves stress granules during stress recovery 9 . Notably, not all membraneless organelles that disappear during mitosis, such as P-bodies and nucleoli, are dissolved by DYRK3. This may suggest a different physico-chemical phenomenon that underlies the formation of these organelles, or a role for other kinases, possibly relatives of DYRK3, that mediate their dissolution.
The organelles that are dissolved by DYRK3 all contain protein and RNA, and form by liquid-liquid phase separation. DYRK3 binds to proteins that are key components of these organelles, and is a proline-directed kinase with broad specificity 23 that phosphorylates multiple serine and threonine residues in unstructured domains 9 . This may affect the electrostatic properties of these domains such that it alters the condensation threshold of these proteins. When the active concentration of DYRK3 becomes high enough relative to its substrates, it triggers a transition from the condensed to the dissolved phase, which will exist as long as this ratio stays sufficiently high. The ratio can be modulated in multiple ways. At the onset of mitosis, the loss of the nucleus-cytoplasm compartment boundary is exploited to alter the DYRK3-to-substrate ratios such that it results in a phase transition. For some organelles, degradation of the dissolvase is used to trigger a phase transition in the opposite direction. Thus, progression through the cell Article reSeArcH cycle can be conceived as a process in which cells cycle through a phase diagram (Fig. 6) . Also, when compartment boundaries stay intact, a specific accumulation or depletion of substrate in one compartment may alter the ratio sufficiently to induce a phase transition which may occur during cellular stress 24 . In addition, the ratio could be altered by increasing the abundance or activity of DYRK3 by specific upstream regulators, which could be coupled to different physiological processes such as the cell cycle 23, 25 . We currently do not understand how at the end of mitosis, and upon degradation of DYRK3, aberrant co-condensation is prevented. One possibility is that the kinetics or regulation of the dephosphorylation of DYRK3-phosphorylated residues in proteins is component-or compartment-specific, as may be the case for the levels of dephosphorylation required to initiate phase transition. In addition, cytoplasm and nucleus compartment boundaries are re-established at this time, which may contribute to preventing aberrant co-condensation.
Multiple aspects of mitosis are compromised when the DYRK3-tosubstrate ratio cannot display its natural dynamics. Increases in the ratio allow the release of mitotic regulators from liquid-unmixed compartments as cells enter mitosis and prevent their aberrant co-condensation during mitosis. In addition, preventing co-condensation during mitosis could be important to ensure homogeneous distribution of proteins and RNA between daughter cells during symmetric cell division, which may then be additionally regulated to achieve differential condensation points in daughter cells during asymmetric cell division 3, 10, 26 . Finally, through its ability to control the condensation of multiple compartments, DYRK3 may link structural and functional roles for RNA, transcription and splicing to the assembly of the mitotic spindle [27] [28] [29] , and be involved in the maintenance of the pericentriolar matrix. We propose that DYRK family kinases represent a novel, evolutionarily conserved class of regulators that controls liquid-liquid unmixing phenomena in cells, which are crucial for a variety of cell-physiological processes.
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MEthodS
Cell culture. HeLa cells were a gift from M. Zerial, HeLa-FlpIn-Trex 30 cells were a gift from I. Dikic and HEK293T cells were from ATCC (Molsheim Cedex). HeLa and HEK293T cells were maintained in 10-cm dishes in DMEM supplemented with 10% fetal bovine serum (Sigma-Aldrich) and l-glutamine (Sigma-Aldrich). HeLa-FlpIn-Trex cells were maintained in 10-cm dishes in DMEM supplemented with 10% tetracycline-free fetal bovine serum (Clonetech Laboratories), l-glutamine and blasticidin (1 μg ml −1 , Santa Cruz). HeLa-FlpIn-Trex cells expressing EGFP-DYRK3(WT) were induced using doxycycline (Sigma) with indicated time and concentration. All cells were maintained in a humidified incubator at 37 °C under 5% CO 2 . All cell lines were regularly tested for mycoplasma contaminations. Test results were negative. For imaging experiments, cells were grown in 96-well plates (Greiner Bio-One International). Inhibitors. GSK-626616 (PubChem CID: 15981157) was obtained from Tocris Bioscience. DMSO was from Sigma-Aldrich (D2438). The following inhibitors were used in this study: GW 843682X (Tocris Bioscience, 2977), ZM 447439 (Tocris Bioscience, 2458), barasertib (Selleck Chemicals, S1147), volasertib (Selleck Chemicals, S2235), VX-680 (Selleck Chemicals, S1048), TCA 2317 HCl (Tocris Bioscience, 4066), KHCB19 (Tocris Bioscience, 4262), KHCB19 (Calbiochem, Merck Millipore, 219511), TG003 (Tocris Bioscience, 4336), SRPIN340 (Santa Cruz, sc-394310) and SRPIN340 (Tocris Bioscience, 5063). Prior to inhibitor treatments, cells were washed and serum-deprived for 2 h.
Generation of HeLa-FlpIn-Trex expressing EGFP-DYRK3(WT).
HeLaFlpIn-Trex cells were co-transfected with plasmids, pcDNA5/FRT/TO-EGFP-DYRK3(WT) and Flp recombinase expression vector (pOG44) for 48 h, and then selected with hygromycin (250 μg ml and supplemented with 10% dialysed fetal bovine serum (PAA Laboratories), 4 mM Glutamax and 1 mM sodium pyruvate. Cells were maintained in a humidified incubator under 5% CO 2 at 37 °C. SILAC quantitative pull-down assays. To study interaction partners of DYRK3, a label-swap SILAC pull-down experiment was set up as depicted in Extended Data Fig. 1a . Plasmids containing EGFP only or EGFP-DYRK3(WT) were transiently transfected into SILAC-labelled HEK293T cells using the linear polyethylenimine (PEI) transfection reagent (Polysciences). Cells of different SILAC states were collected 48 h after transfection and lysed separately using a Dounce homogenizer in lysis buffer containing 25 mM Tris/HCl pH 7.4, 125 mM KCl, 1 mM MgCl 2 , 1 mM EGTA/KOH pH 8.0, 5% glycerol, 1% Triton X-100 and freshly added protease inhibitor cocktail (Roche). The cleared lysates were then incubated with anti-EGFP agarose beads (Chromotek) at 4 °C for 90 min. After that, the beads were washed two times in buffer I (25 mM Tris/HCl pH 7.4, 125 mM KCl, 1 mM MgCl 2 , 1 mM EGTA/KOH pH 8.0, 5% glycerol, 0.1% Triton X-100) with one wash in buffer II (1 mM Tris/HCl pH 7.4, 150 mM KCl, 1 mM MgCl 2 ). Beads of different SILAC states were combined during the final washing step. Proteins were then eluted by heating the beads to 90 °C in 8 M guanidinium chloride and precipitated in ethanol at 4 °C.
A separate triple-SILAC pull-down experiment was carried out to study the effect of the DYRK3 inhibitor (GSK-626616) on DYRK3 interactions as shown in Extended Data Fig. 1b . In brief, 24 h post-transfection, cells were further treated with 10 μM GSK-626616 inhibitor for 2 h or not treated. The remaining steps of the pull-down experiment were then conducted as described above.
Precipitated proteins were resolubilized in 6 M urea/2 M thiourea buffer (10 mM HEPES pH 8.0). Proteins were then reduced by dithiothreitol and alkylated by iodoacetamide in the dark, with sequential digestion in solution using lysyl endopeptidase (Lys-C, Wako) for 3 h and trypsin (Promega) overnight at room temperature as reported previously 31 . Peptides were desalted and purified by solid phase extraction in C18 StageTips 32 . Liquid chromatography with tandem mass spectrometry. Peptide separation was done online by reversed phase chromatography using an in-house packed column (inner diameter: 75 μm; ReproSil-Pur C18-AQ 3-μm resin, Dr. Maisch GmbH) through a 120-min gradient of acetonitrile (8-50%) with 0.1% formic acid at a nanoflow rate of 200 nl min . Eluted peptides were sprayed directly by electrospray ionization into a Q Exactive Plus Orbitrap mass spectrometer (Thermo Fisher Scientific). Mass spectra were acquired in data-dependent mode using a top10 sensitive method. Each duty cycle consisted of one full scan (resolution: 70,000, target value: 3 × 10 6 , scan range: 300 to 1,700 m/z) and ten tandem mass spectrometry scans of fragment ions produced via higher energy collision dissociation (HCD; resolution: 35,000, target value: 5 × 10
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, maximum injection time: 120 ms, isolation window: 4.0 m/z). Precursor ions with unassigned or +1 charge state were not selected for fragmentation scans. Dynamic exclusion time was 30 s.
Mass spectrometry data processing. All mass spectrometry raw data were processed using MaxQuant software package (v.1.5.5.1) 33 with the built-in Andromeda search engine 34 . Spectral data were searched against a target-decoy database containing the forward and reverse protein sequences of UniProt human proteome release 2016_06 (92,578 entries), EGFP and the default list of 245 common contaminants. Corresponding SILAC labels were selected for the double-or triple-SI-LAC experiment. A maximum of three SILAC-labelled amino acids were allowed for each peptide. Trypsin/P specificity was assigned. Carbamidomethylation of cysteine was chosen as fixed modification. Methionine oxidation and protein N-terminal acetylation were set as variable modifications. A maximum of two missed cleavages were tolerated. Minimum peptide length of seven amino acids was required. Each protein group must contain at least one unique peptide. False discovery rate (FDR) was set to 1% for both peptide and protein identifications.
For SILAC protein quantification, minimum ratio count was set to one. Both the unique and razor peptides were used for quantification. The 're-quantify' function was switched on. The 'advanced ratio estimation' option was also chosen. Bioinformatic data analysis. All data analyses were performed in the R statistical environment (v.3.3.1). To normalize the pull-down data, protein ratios were first log-transformed. Under the assumption that the majority of detected proteins were non-specific background binders, the distribution of protein ratios was assessed using kernel density estimation to find the peak density. Protein ratios were then normalized by adjusting to the point at which the peak density was found. For the triple-SILAC pull-down data, proteins were further filtered to retain only those with a normalized heavy labelled/light labelled or medium labelled/light labelled log 2 ratio greater than the cut-off value of one. The log-transformed heavy labelled/medium labelled ratios were then re-scaled with respect to the DYRK3 heavy labelled/medium labelled ratio (Extended Data Fig. 1c) .
Gene Ontology annotation for categorizing the detected DYRK3 interaction partners was downloaded on 28th June 2016 from the QuickGO database 35 provided by the European Bioinformatics Institute. The list of stress-granule components was obtained from previously published work 36 .
To assess phosphorylation level changes of detected DYRK3 specific binders during the cell cycle, quantitative phosphoproteomic data of the human cell cycle were downloaded from a previous study 37 . The data were filtered sequentially to retain: (1) phospho-sites with high confidence in localization probability (class I) 38 ; (2) phospho-sites that were regulated over cell cycle (changed by at least two folds from highest to lowest amounts); and (3) phospho-sites belonging to proteins that were identified as DYRK3-specific interaction partners in our study. The phospho-site ratios already normalized by changes in protein abundance were then re-scaled by z-score transformation and plotted as a heat map (Extended Data  Fig. 2d) .
The standard error of the median in Fig. 1 and Fig. 5 was computed on the basis of the bootstrap (1,000 times) sampling distribution of corresponding log-transformed ratios of peptide evidence. The protein ratio of ZNF207 in Fig. 5c is determined by a regression analysis using the 'advanced ratio estimation' function in MaxQuant.
Prediction of the protein low complexity region (LCR) was performed using the SEG algorithm with default parameters 39 . Cell synchronization. Cells were synchronized in mitosis (M) by treatment with 2 mM thymidine (Sigma-Aldrich) for 22 h, washed three times with PBS, released from thymidine block for 5 h in fresh medium and then treated with nocodazole (25 ng ml −1 ) (Sigma-Aldrich) for 14 h. For time-course experiments, mitotic cells were harvested by shake-off, and then centrifuged for 3 min at 300g. Cells were then washed three times with normal medium and released in normal medium for the indicated times. Plasmids. Generation of full-length DYRK3 plasmids, pcDNA5-EGFP-DYRK3(WT) and pcDNA5-EGFP-DYRK3(K218M) has been reported previously 9 . pcDNA5-EGFP-NLS(SV40)-DYRK3(WT) and pcDNA5-EGFP-NLS(SV40)-DYRK3(K218M) constructs were generated by annealing oligonucleotides 5′-CCGGTTACCGAAG AAGAAGCGAAAGGTACA-3′ and 5′-TTACCGAAGAAGAAGCGAAAGG TACACCGG-3′, and ligating the product into pcDNA5-EGFP-DYRK3(WT) and pcDNA5-EGFP-DYRK3(K218M) plasmids using AgeI restriction site. The NLS(SV40) is the nuclear localizing signal derived from simian virus (SV40) large T antigen. The pcDNA5-EGFP-NLSmut-DYRK3 plasmid was generated by site-directed mutagenesis in pcDNA5-EGFP-DYRK3(WT) using primer pair 5 ′-GC TT GT GG GG GG TC GC TC AG CT GC GG GT GC AG CG GC GGGTC CCCCAGGCAGC-3′ and 5′-GCTGCCTGGGGGACCCGCCGCTGCACCC GCAGCTGAGCGACCCCCCACAAGC-3′. mCherry-SRRM1 was generated by amplifying SRRM1 from Flag-SRRM1 40 (Addgene plasmid, 11305) using primer pair 5′-GCTAAGCTTCGATGGACGCGGGATTTTTCCGCGGAAC-3′ and 5′-CATGGTACCTTATTAAGACTGTGGGGACACTTGGGCCTTC-3′, and inserting the product into the mCherry2-C1 plasmid (gift from M. Davidson, Addgene plasmid, 54563) using HindIII and KpnI restriction sites. The pcDNA5/FRT/TO-EGFP-DYRK3(WT) vector was generated Article reSeArcH by amplifying EGFP-DYRK3 from pcDNA5-EGFP-DYRK3(WT) using primer pair 5′-GGTGGTACCCGCCACCATGGTGAGCAAGGGCG-3′ and 5′-GCTGGATCCTTATTAGCTAATCAGTTTTGGCAATACACT-3′, and inserting the product into the pcDNA5/FRT/TO plasmid 9 using KpnI and BamHI restriction sites. RFP-DYRK3(WT) and RFP-DYRK3(K218M) were generated by amplifying them from pcDNA5-EGFP-DYRK3(WT) and pcDNA5-EGFP-DYRK3(K218M), respectively, using primer pair 5′-ATCGAATTCTATGAAGTGGAAAGAGAAGTTGGGGGATG-3′ and 5′-GGTACCTTATTAGCTAATCAGTTTTGGCAATACAC-3′, and inserting the products into the mRFP-C1 plasmid (a gift from R. Campbell, M. Davidson and R. Tsien, Addgene plasmid 54764) using EcoRI and KpnI restriction sites. Fulllength SRRM2 (NM_016333.3) was synthesized by Genscript and inserted into the mCherry2-N1 plasmid (gift from M. Davidson, Addgene plasmid 54517) using KpnI and AgeI restriction sites. EGFP-PCM1 (1-1468) was a gift from A. Merdes. EGFP-3XNLS 41 was a gift from D. Mullins (Addgene plasmid, 58468). pmScarlet_NES_C1 42 was a gift from D. Gadella (Addgene plasmid, 85060). 1436 pcD-NA3-Flag-HA was a gift from W. Sellers (Addgene plasmid, 10792). HA-CDH1 43 and HA-CDC20 43 were a gift from M. Kirschner (Addgene plasmid, 11596). Plasmid transfections. Transfections were performed with the indicated plasmids using either GeneJuice reagent (EMD Millipore) or Lipofectamine 2000 (Thermo Fisher Scientific) according to the manufacturer's instructions. RNA fluorescent in situ hybridization. Fluorescent in situ hybridization (FISH) was performed with ATTO 488-labelled 18-nucleotide long oligo-dT probe (Microsynth) for detecting polyA-mRNA. Probe hybridization was performed using the reagents and protocol provided by the manufacturer (LGC Biosearch Technologies). Cells were grown in 96-well plates, fixed by adding 4% PFA for 10 min, and permeabilized with 70% ethanol for 6 h at 4 °C. Cells were then washed with wash buffer, and incubated with the probe in hybridization buffer for 6 h at 37 °C. The cells were washed again with wash buffer and then processed for immunofluorescence. RNA interference. Cells were reverse-transfected using Lipofectamine RNAimax (Thermo Fisher Scientific) according to manufacturer instructions, and grown in 96-well plates. Three silencer-select short interfering RNA (siRNA) against DYRK3 (5′-CGGAUUUUGGAGCAUCUUA-3′, 5′-CCAUCUAGCUUAUCGAUAU-3′and 5′-GAAAAGACAUGGAGUUAUU-3′) were pooled together (Thermo Fisher Scientific). Positive (KIF11) and negative control silencer-select siRNA were from Thermo Fisher Scientific. 1 pmol siRNA was added per well of a 96-well plate. Cells were fixed 72 h post transfection. Imaging. Imaging was carried out on an automated spinning disk microscope from Yokogawa (Cell Voyager 7000), with an enhanced CSU-X1 spinning disk (Microlens-enhanced dual Nipkow disk confocal scanner, wide view type), a 40× 0.95 NA Olympus objective, a 60× 1.2 NA Olympus water-immersion objective and Andor sCMOS cameras (Andor, 2,560× 2,160 pixels). Live-cell imaging experiments were performed with Yokogawa (Cell Voyager 7000) with a 60× 1.2 NA Olympus water-immersion objective. All cells were maintained in a humidified environment at 37 °C under 5% CO 2 for live-cell imaging experiments. For nucleo-cytoplasmic dilution experiments (Fig. 4b, Extended Data Fig. 8a-d) , HeLaFlpIn-Trex cells were transfected with the indicated plasmids for 6 h, synchronized in G1/S using thymidine (2 mM, 22 h), and then released into normal medium for 6 h before imaging. EGFP-DYRK3 expression was induced with doxycycline (1 μg ml , Thermo Fisher Scientific) was added to stain DNA, 1 h before imaging. Six Z-stacks (1 μm apart) were acquired at each time point and data was stored as individual stacks. For other experiments, images were stored as maximum intensity projection. For mitotic arrest experiments, cells were transfected with indicated plasmids overnight, followed by thymidine treatment (2 mM, 22 h), and then released into normal medium for 6 h. Cells were then treated with nocodozole (25 ng ml ) for 6 h in serum-deprived medium to arrest cells in pro-metaphase. For experiments measuring the mean intensity of SRRM2-mCherry during mitotic granule formation (Extended Data Fig. 6b, c) , cells were imaged with 60× 1.2 NA objective, and acquired Z stacks (0.45 μm apart, 43 stacks) were stored as individual files. For SRRM2-mCherry and mCherry-SRRM1 granule fusion experiments in mitotic cells, acquired Z-stacks (1 μm apart, 11 stacks) were stored as individual files. For experiments to calculate the mitotic length, Hoechst 33342 (0.5 μg ml , Thermo Fisher Scientific) was added to stain DNA, 1 h before imaging. Time-lapse imaging was performed with a time interval of 10 min. Image analysis. Images were processed using ImageJ (https://rsb.info.nih.gov/ij/). For quantifying mitotic granules (SC35 granules, PABP granules and PCM1 granules) in metaphase, cells were manually segmented and mean cell intensity was determined for SC35, PABP and PCM1. Granules were determined using the FIJI 3D Objects Counter plugin, with an intensity threshold of 2.5× the mean mitotic cell intensity. We implemented an adjoining pixel cut-off of (8 pixels for SC35 granules, 12 pixels for PABP granules and 16 pixels for PCM1 granules; pixel size 161.3 nm × 161.3 nm) 8 . The 90th percentile of granule numbers for the DMSO control data in Fig. 2a, b were used as the cut-off for quantification of Extended Data Fig. 3g (three for SC-35 granules and one for PABP granules). Mitotic granules were observed and quantified in metaphase cells (identified on the basis of DAPI staining). For nuclear dilution experiments of EGFP-3×NLS, mCherry-SRRM1 and EGFP-DYRK3, the nuclei of cells in G2 phase were segmented on the basis of Hoechst signal. For cytoplasmic dilution experiments of pmScarlet-NES and EGFP-DYRK3, nuclear segmentation was performed on the basis of Hoescht signal, and the cell segmentation was performed using the cytoplasmic fluorescent signal from these proteins. For cytoplasmic dilution experiments of PCM1 (1-1468), cells were co-transfected with a plasmid expressing mCherry protein.
Nuclear segmentation was performed on the basis of Hoescht signal, and the cell segmentation was performed using the cytoplasmic fluorescence signal of mCherry. Mitotic cells were segmented using the cytosolic fluorescence signal of the respective proteins. Mean nuclear or cytoplasmic intensity at each time-point is the mean intensity from four Z-stacks (1 μm apart). The mean nuclear intensity at each time point was normalized to the intensity at the −60-min time-point. For experiments measuring the mean intensity of SRRM2-mCherry during mitotic granule formation (Extended Data Fig. 6b, c) , sum projection of the Z-stacks (0.45 μm apart, 43 stacks) was performed in ImageJ. Mitotic cells that were entirely captured within the Z-stacks during the course of the time-lapse movie were used for quantification.
For experiments performed in Extended Data Fig. 1d , cell and nuclear segmentation was performed using CellProfiler 44 . Mitotic, border, missegmented cells, and cells with multiple nuclei were discarded using the supervised machine-learning tool, CellClassifier 45 . Mean intensity features were extracted from segmented cells and used for quantification.
Mitotic length was calculated from prophase/pro-metaphase to anaphase on the basis of Hoescht signal. All data analyses were performed in Microsoft Excel and the R statistical environment. Exposure and image processing has been performed similarly for all sub-figures in each panel. Images have been rescaled similarly in all sub-figures in a panel except Fig. 4e . In Fig. 4e the images of mCherry-SRRM1 in M phase are rescaled differently compared to S and G2 phase for better visualization of condensed and dissolved states of SRRM1. Background subtraction was performed on images by calculating the mean background intensity outside the cells.
Statistical analysis was performed using Welch's two-sided t-test in the R statistical environment using the default t-test function. Phase diagram experiment. For the phase diagram experiment (Fig. 4c-e) , HeLaFlpIn-Trex cells were co-transfected with pcDNA5/FRT/TO-EGFP-DYRK3(WT) and mCherry-SRRM1 for 24 h and then induced with doxycycline (1 μg ml) for 2 h before imaging. Hoechst 33342 (0.5 μg ml −1 , Thermo Fisher Scientific) was added to stain DNA, an hour before imaging. Time-lapse imaging was performed with a time interval of 15 min.
The phase diagram (Fig. 4c ) was built by randomly selecting cells from multiple time points from the start, middle and end of the time-lapse movie. Nuclear segmentation was manually performed on the basis of Hoescht signal, and the mean nuclear intensity of EGFP-DYRK3 and mCherry-SRRM1 was calculated from the maximum intensity projections. The nuclear intensities were used to determine the phase diagram. Cells were classified on the basis of SRRM1 granules being in a dissolved (≤3 granules) or condensed state (>3 granules). Cells in interphase (Fig. 4d) or cells transitioning from interphase to mitosis (Fig. 4e) from the same time-lapse experiment were mapped on the determined phase diagram. FRAP analysis. HeLa-FlpIn-Trex cells were grown on 8-well chambers (Ibidi GmbH, Germany). Cells were transfected with the indicated plasmids for 24 h, for experiments in interphase cells. Photobleaching experiments in interphase cells were performed in serum-deprived medium. For mitotic experiments, cells were transfected overnight with indicated plasmids, with G1-S arrest using thymidine (2 mM). mCherry-SRRM1 transfected cells were released in serum-deprived medium and monitored during mitosis. SRRM2-mCherry transfected cells were arrested in mitosis using nocodazole (in serum-deprived medium). Photobleaching was performed on a Leica SP5 Mid UV-VIS equipped with a 63× 1.4 NA, oil, PlanApochromat objective. Cells were maintained at 37 °C under 5% CO 2 during the course of experiment. A defined region was bleached twice at full laser power. Recovery could not be monitored for long durations because of mitotic granules moving out in the Z-direction. Recovery curves are therefore plotted for durations in which the granules seemed not to move in the Z-direction. FRAP analysis was performed using ImageJ. Immunofluorescence. Cells were grown in 96-well plates and fixed by adding 4% PFA (Electron Microscopy Sciences) for 20 min and then permeabilized with 0.2% Triton X-100 for 20 min. The cells were blocked with 1% BSA in PBS (blocking buffer), incubated with primary antibodies in blocking buffer for 2 h at room temperature, and then incubated with Alexa-Fluor labelled secondary antibody (Life Technologies) in blocking buffer for 1 h at room temperature. Nuclei were stained using DAPI (Life Technologies). Staining for γ-tubulin and 
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